Company: BKYI
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001437749-25-016136
Chunk: 6

Company: BIO KEY INTERNATIONAL INC
Filing Date: 2025-05-12
Form: 424B3
Chunk 6
---
us will be received by the selling stockholder. We will not receive any of the proceeds from any sale of the shares of common stock offered by this prospectus. If all of the Series A Warrants and Series B Warrants exercisable for shares of common stock offered hereby are exercised, we will receive aggregate gross proceeds of $6,647,086.20 which we expect to use for working capital purposes and general corporate purposes, including repayment of a portion of the Company’s outstanding secured note. See “Use of Proceeds”. |
| Listing of common stock:                                                                                                                                            | Our common stock is listed on the Nasdaq Capital Market under the ticker symbol “BKYI”.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Risk factors:                                                                                                                                                       | Investing in our securities involves a high degree of risk and purchasers of our securities may lose their entire investment. See the information under the caption “Risk Factors” beginning on page 5 of this prospectus and the other information included elsewhere in this prospectus and incorporated by reference herein for a discussion of factors you should consider before deciding to invest in our securities.                                                                                                                                                                                      |

<div align='center'>4</div>

The number of shares of our common stock to be outstanding after this offering is based on 5,814,041 shares of our common stock outstanding as of April 23, 2025, plus an aggregate of 3,091,668 shares of common stock issuable upon exercise of Series A warrants and Series B warrants, and excludes as of such date:

| ● | 3,007 shares of common stock issuable upon the exercise of stock options, with a weighted-average exercise price of $197.31 per share;           |
| ● | 2,739,362 shares of common stock issuable upon the exercise of outstanding warrants, with a weighted-average exercise price of $11.12 per share; |
| ● | 421,905 shares of common stock issuable on exercise of warrants with an exercise price of $3.15 per share;                                       |
| ● | 31,131 shares of common stock issuable upon exercise of pre-funded warrants with an exercise price of $0.018 per share;                          |
| ● | 529 shares of common stock reserved for future issuance under our 2015 Equity Incentive Plan;                                                    |
| ● | 35,050 shares of common stock reserved for future issuance under our 2021 Employee Stock Purchase Plan;                                          |
| ● | 155,957 shares of common stock reserved for future issuance under